• E-mail :[email]
  • Phone : +33153739566
  • Location : Paris, France
Last update 2011-04-05 10:21:52.503

Michel Bessodes PhD Organic Chemistry

Course and current status

Present situation:

Head of the team "Design, synthesis and validation of vectors for targeted therapy and imaging

" , U1022 (D. Scherman)


Research director at the "Institut National de la Santé et de la Recherche Médicale"



Scientific Career :


2010-          : Leader of the team "Design, Synthesis and Validation of Vectors for Targeted Therapy and Imaging” U1022- INSERM

2003 - 2009: Leader of the team "Chemistry and Physicochemistry of Vectorisation" in U640 - INSERM

1998 – 2002: Leader of the team " Organic Synthesis of Targeted Vectors " in

  UMR7001 (Aventis Pharma - Vitry)

1991 :              Research Director (DR2) at l’INSERM

1981 :              Senior Research at INSERM

1979-1980 :     postdoctoral fellowship from the National Science Foundation

1978 :              Research Fellow at INSERM

1977 :              grant from the National Institute of Health (3 mois)

1977:               grant from the "Fondation pour la Recherche Médicale Francaise"

1974 -1976:     grant from the "Ligue Nationale Francaise contre le Cancer"

Scientific summary

Scope of interest:

Gene and chemical drugs vectorisation, membranes receptors ligands, targeting of tumors and of tumoral and inflammatory endothelium, chemistry and physico-chemistry of vectors active principle assembly /, gene therapy, cancer.


Research themes:


Vectors for targeted therapy


-          Releasing studies of nucleic acids, (DNA, pDNA, siRNA) or other active principles (ATP, antivascular drugs) associated with vectors administered iv or topically.


-          Conception, synthesis and studies of original molecular vectors and their targeting


Vectors for imaging


-          Nanosized contrast agents for magnetic resonance imaging (MRI), functionalization targeting and in vivo validation.


-          Delayed luminescent nanoparticles, functionalization targeting and in vivo validation.



-          Proteic or non proteic nanoparticulate systems for hepatocyte targeting and pet scan imaging.

Image d’exemple